1. Cell Cycle/DNA Damage
    Cytoskeleton
    Autophagy
  2. Microtubule/Tubulin
    Autophagy

Vinorelbine (Synonyms: KW-2307 base)

Cat. No.: HY-12053
Handling Instructions

Vinorelbine is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.

For research use only. We do not sell to patients.
Vinorelbine Chemical Structure

Vinorelbine Chemical Structure

CAS No. : 71486-22-1

Size Inquiry
10 mg Get quote for price and lead time
50 mg Get quote for price and lead time

* Please select Quantity before adding items.

Other In-stock Forms of Vinorelbine:

Other Forms of Vinorelbine:

  • Biological Activity

  • Protocol

  • Technical Information

  • References

Description

Vinorelbine is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.

In Vitro

Vinorelbine (0.5-5 nM) inhibits cell proliferation by 50% (IC50) at concentrations of 1.25 nM. At concentration of 8 nM vinorelbine, no cells are in anaphase[1]. Vinorelbine time-dependently induces the p53 and p21WAFI/CIP1 expression in androgen-dependent (AD) and- independent (AI) prostate cancer cell lines. Vinorelbine stimulates reporter genes in a concentration-dependent manner[2].

In Vivo

After vinorelbine treatment, the first neutropenicepisode occurred after the first (4 dogs), second (1), or sixth(1) vinorelbine treatment in the dogs[3]. Vinorelbine is tolerated at a weekly interval in tumor-bearing cats, with an MTD of 11.5 mg/m2[4].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00176488 University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey Breast Cancer June 2003 Phase 2
NCT00912275 National Taiwan University Hospital|GlaxoSmithKline Metastatic Breast Cancer May 2009 Phase 1|Phase 2
NCT01497860 Eugene Hwang|Children's Research Institute Low-grade Glioma July 2011 Phase 2
NCT03007992 Johannes Gutenberg University Mainz|Pierre Fabre Pharma GmbH Metastatic Breast Cancer December 2016 Phase 2
NCT02139904 Wales Cancer Trials Unit|Pierre Fabre Laboratories Mesothelioma March 1, 2016 Phase 2
NCT02144194 Cancer Research Group - Collaborative Group, Beirut, Lebanon. Breast Cancer March 2012 Phase 2
NCT00702182 National Cancer Centre, Singapore Non-Small Cell Lung Cancer April 2008 Phase 1
NCT02197637 Centre Oscar Lambret|National Cancer Institute, France|Pierre Fabre Laboratories Low-Grade Glioma May 2014 Phase 2
NCT00958724 Puma Biotechnology, Inc. Advanced Malignant Solid Tumors July 2009 Phase 1
NCT00706069 Hellenic Oncology Research Group|University Hospital of Crete Metastatic Breast Cancer June 2008 Phase 1
NCT00801151 Institut Claudius Regaud|Merck Sharp & Dohme Corp. Malignant Solid Tumour January 2009 Phase 1
NCT00870532 National Cancer Centre, Singapore Non-Small Cell Lung Cancer June 2008 Phase 1
NCT01220284 Southern Europe New Drug Organization|Agennix|Pierre Fabre Laboratories Advanced Solid Tumors February 2008 Phase 1
NCT00215462 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center Esophageal Cancer|Gastric Cancer|Stomach Cancer June 2000 Phase 2
NCT00003828 Southwest Oncology Group|National Cancer Institute (NCI) Melanoma (Skin) May 1999 Phase 2
NCT02985203 Guangdong Association of Clinical Trials Lung Neoplasm Malignant November 2016 Phase 2
NCT00513058 UNICANCER Breast Cancer June 2007 Phase 1
NCT01196559 The Catholic University of Korea|Korean Cancer Study Group Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer January 2011 Phase 2
NCT02658084 University of Miami|Genentech, Inc. Breast Cancer|Metastatic Breast Cancer April 12, 2017 Phase 1|Phase 2
NCT01730677 National Cancer Center, Korea|Asan Medical Center|Chung-Ang University|Korea University Anam Hospital|Samsung Medical Center|Seoul National University Hospital|Seoul National University Bundang Hospital Metastatic Breast Cancer July 2012 Phase 2
NCT00755170 Hellenic Oncology Research Group|University Hospital of Crete Non Small Cell Lung Cancer November 2008 Phase 2
NCT00754702 University Hospital of Crete Breast Cancer October 2008 Phase 2
NCT02768415 Chinese Academy of Medical Sciences Breast Cancer June 2016 Phase 2
NCT02802748 SOLTI Breast Cancer Research Group|Pierre Fabre Laboratories Breast Cancer July 2016 Early Phase 1
NCT00278070 Hellenic Cooperative Oncology Group|University of Ioannina Breast Cancer|Non Small Cell Lung Cancer|Prostate Cancer January 2006 Phase 2
NCT00764972 McGill University Metastatic Breast Cancer October 2007 Phase 1|Phase 2
NCT01060514 Northwestern University|Robert H. Lurie Cancer Center Metastatic Non Small Cell Lung Cancer|Metastatic Breast Cancer February 2010 Phase 1
NCT00709618 GlaxoSmithKline Neoplasms, Breast June 2008 Phase 2
NCT01185509 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Genentech, Inc. Breast Cancer|Metastatic Breast Cancer November 2010 Phase 2
NCT00151086 University of Michigan Cancer Center|GlaxoSmithKline Prostate Cancer December 2001 Phase 1|Phase 2
NCT01238029 Sponsor GmbH|iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Arbeitskreis Klinische Studien|GlaxoSmithKline Metastatic Breast Cancer|HER2 Positive|First or Second Line Therapy|Failure or Contraindication of Trastuzumab Therapy October 2010 Phase 1
NCT02619929 Pierre Fabre Pharma GmbH|Winicker Norimed GmbH Non-Small-Cell Lung Cancer|Breast Cancer February 2016
NCT01155258 University of Southern California|Wyeth is now a wholly owned subsidiary of Pfizer Extensive Stage Small Cell Lung Cancer|Hereditary Paraganglioma|Male Breast Cancer|Malignant Paraganglioma|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Pheochromocytoma|Pancreatic Polypeptide Tumor|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Endometrial Carcinoma|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Neuroendocrine Carcinoma of the Skin|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovaria June 2010 Phase 1
NCT00694200 Hellenic Oncology Research Group|University Hospital of Crete Breast Cancer April 2008 Phase 2
NCT00017394 National Cancer Institute (NCI) Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer March 2001 Phase 2
NCT02319577 IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy Non Small Cell Lung Cancer March 2012 Phase 2
NCT00165334 Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Bristol-Myers Squibb Non-small Cell Lung Cancer June 2005 Phase 2
NCT01161368 Central European Cooperative Oncology Group Metastatic Breast Cancer September 2010 Phase 2
NCT02791373 University Hospital Inselspital, Berne Multiple Myeloma|Amyloidosis March 2014 Phase 2
NCT01305941 UNC Lineberger Comprehensive Cancer Center|Novartis Pharmaceuticals HER-2 Positive Breast Cancer September 2011 Phase 2
NCT01128543 GlaxoSmithKline Cancer April 2009 Phase 2
NCT01848613 Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Non-small Cell Lung Cancer Metastatic October 2012 Phase 4
NCT01214616 Boehringer Ingelheim Neoplasms October 2010 Phase 1
NCT01839032 Pierre Fabre Medicament Lung Cancer May 2005 Phase 2
NCT00706030 Puma Biotechnology, Inc. Breast Cancer|Advanced Malignant Solid Tumors April 2008 Phase 1|Phase 2
NCT00545948 Duke University|Eli Lilly and Company Carcinoma, Non-Small-Cell Lung December 2007 Phase 2
NCT00532623 National Cancer Center, Korea Metastatic Breast Cancer May 2004 Phase 2
NCT00180947 Gustave Roussy, Cancer Campus, Grand Paris Rhabdomyosarcomas|Neoplasms, Connective and Soft Tissue|Ewing Tumor|Osteosarcomas|Neuroblastomas|Medulloblastomas June 2003 Phase 2
NCT03188159 National University Hospital, Singapore|National Cancer Centre, Singapore|KK Women's and Children's Hospital Ovarian Cancer|Fallopian Tube Cancer July 1, 2017 Phase 2
NCT00008333 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Lung Cancer April 2001 Phase 2
NCT00022152 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Breast Cancer November 2001 Phase 2
NCT01528826 Fudan University Breast Cancer December 2011 Phase 2
NCT00675597 Memorial Sloan Kettering Cancer Center|Sanofi Lung Cancer May 2008
NCT01941771 University of Aarhus|Pierre Fabre Laboratories Breast Cancer June 2012 Phase 2
NCT00629148 Fudan University Breast Cancer|Metastasis, Neoplasm August 2007 Phase 2
NCT01749072 Peking Union Medical College Hospital Non-small Cell Lung Cancer|Effects of Chemotherapy December 2012 Phase 2
NCT00256282 University of California, Irvine|Bayer Metastatic Melanoma April 2003 Phase 2
NCT00441922 Hellenic Oncology Research Group|University Hospital of Crete Non Small Cell Lung Cancer January 2003 Phase 3
NCT00003963 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Genentech, Inc. Lymphoma May 1999 Phase 2
NCT01013740 Novartis Pharmaceuticals|Novartis Cancer November 25, 2009 Phase 2
NCT00908869 Institut Paoli-Calmettes Advanced Neoplasm May 2006 Phase 1
NCT00295672 University Hospital, Brest|Fabre Clinic Lung Neoplasm February 2006 Phase 2
NCT02555007 Assistance Publique Hopitaux De Marseille Non Small Cell Lung Cancer (NSCLC)|Malignant Pleural Mesothelioma (MPM) August 2015 Phase 1
NCT00134641 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital Sarcoma, Soft Tissue February 2003 Phase 2
NCT00431106 Hellenic Oncology Research Group|University Hospital of Crete Breast Cancer April 2002 Phase 3
NCT00737867 The Norwegian Lung Cancer Study Group Advanced Non-Small Cell Lung Cancer September 2007 Phase 3
NCT01520103 AIO-Studien-gGmbH|iOMEDICO AG|Novartis Pharmaceuticals Her2-negative Metastatic Breast Cancer|Her2-negative Locally Advanced Breast Cancer January 2012 Phase 2
NCT00828074 City of Hope Medical Center|National Cancer Institute (NCI) Breast Cancer November 2008 Phase 1|Phase 2
NCT02176369 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Regione Lombardia Non-small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV February 2013 Phase 2
NCT02628613 Fudan University Breast Cancer April 2015 Phase 3
NCT00256711 AstraZeneca Non-Small-Cell Lung Carcinoma July 2004 Phase 2
NCT00003234 Children's Oncology Group|National Cancer Institute (NCI) Brain and Central Nervous System Tumors|Neuroblastoma|Sarcoma May 1998 Phase 2
NCT00906698 Boehringer Ingelheim Neoplasms June 2009 Phase 1
NCT00026494 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Northwestern Memorial Hospital Metastatic Cancer July 2001 Phase 1|Phase 2
NCT00670982 Harold J. Burstein, MD, PhD|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Genentech, Inc.|New Hampshire Oncology-Hematology PA|Lowell General Hospital|Hartford Hospital|Dana-Farber Cancer Institute Breast Cancer May 2008 Phase 2
NCT00602797 University of Nebraska|National Cancer Institute (NCI) Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer December 2007 Phase 2
NCT00192062 Eli Lilly and Company Breast Cancer July 2004 Phase 2
NCT00432562 Mast Therapeutics, Inc.|Synteract, Inc.|Thywill Latam Solutions SRL|OCASA Soluciones Logísticas S.A.|Worldwide Clinical Trials Breast Cancer|Non-small Cell Lung Cancer|Non-Hodgkins Lymphoma February 2007 Phase 1
NCT00372476 Novartis Pharmaceuticals|Novartis Breast Cancer June 2006 Phase 4
NCT01007942 Novartis Pharmaceuticals|Novartis HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer October 2009 Phase 3
NCT01884441 Armando Santoro, MD|Istituto Clinico Humanitas Hodgkin's Lymphoma July 2011 Phase 2
NCT02225470 Eisai Co., Ltd.|Eisai Inc. HER2-Negative Breast Cancer|Triple Negative Breast Cancer|Breast Cancer|Cancer of Breast|Breast Tumors September 2013 Phase 3
NCT00075673 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Breast Cancer November 2003 Phase 1
NCT02730091 Centre Hospitalier Universitaire de Besancon|Pierre Fabre Medicament Breast Cancer February 2016 Phase 3
NCT01439191 Shanghai CP Guojian Pharmaceutical Co.,Ltd. Metastatic Breast Cancer July 2005 Phase 2
NCT00140140 Celgene Corporation|Celgene Stage IV (Metastatic) Breast Cancer August 2005 Phase 1|Phase 2
NCT00093808 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Breast Cancer August 2004 Phase 2
NCT00641160 Metronome Therapeutics Nonhematologic Malignancies March 2008 Phase 1
NCT00453635 Hellenic Oncology Research Group|University Hospital of Crete Breast Cancer December 2003 Phase 2
NCT01531764 University of Magdeburg|Boehringer Ingelheim Carcinoma Breast Stage IV July 2012 Phase 2
NCT02709720 Spanish Lung Cancer Group Lung Cancer April 2016 Phase 2
NCT01109524 Eli Lilly and Company Lung Neoplasms|Carcinoma|Cancer of the Lung|Non-Small-Cell Lung Carcinoma July 2010 Phase 2
NCT00193089 SCRI Development Innovations, LLC|Aventis Pharmaceuticals|GlaxoSmithKline Breast Cancer April 2001 Phase 2
NCT00496275 Genzyme, a Sanofi Company|Sanofi Non Small Cell Lung Cancer August 2006 Phase 1
NCT01565083 Hoffmann-La Roche Breast Cancer April 2012 Phase 2
NCT00146549 Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women's Hospital|North Shore Medical Center|GlaxoSmithKline Breast Cancer|Stage IV Breast Cancer August 2001 Phase 3
NCT00678964 LungenClinic Grosshansdorf Non-Small Cell Lung Cancer June 2006 Phase 2
NCT01684111 Aktion Bronchialkarzinom e.V.|Boehringer Ingelheim Carcinoma, Non-Small-Cell Lung June 2013 Phase 1
NCT01254136 Incyte Corporation Breast Cancer October 2010 Phase 1|Phase 2
NCT00148798 Merck KGaA Non Small Cell Lung Cancer (NSCLC) October 2004 Phase 3
NCT01405079 Guangdong Association of Clinical Trials|Guangdong General Hospital|First Affiliated Hospital, Sun Yat-Sen University|Sun Yat-sen University|Jilin Provincial Tumor Hospital|Liaoning Tumor Hospital & Institute|First Hospital of China Medical University|Chinese PLA General Hospital|Peking Union Medical College Hospital|Peking University People's Hospital|Beijing Chest Hospital|309th Hospital of Chinese People's Liberation Army|Beijing Cancer Hospital|Peking University First Hospital|Tianjin Medical University Cancer Institute and Hospital|Qingdao University|Jiangsu Cancer Institute & Hospital|The First Affiliated Hospital of Soochow University|Fudan University|Shanghai Pulmonary Hospital, Shanghai, China|Zhejiang Cancer Hospital|Zhejiang University|Wuhan Union Hospital, China|Tongji Hospital|West China Hospital|Tang-Du Hospital Non-small Cell Lung Cancer July 2011 Phase 3
NCT00266110 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation Breast Cancer December 2005 Phase 2
NCT02585388 ARCAGY/ GINECO GROUP|Pierre Fabre Laboratories Breast Cancer October 2015 Phase 2
NCT00194727 University of Washington|Hoffmann-La Roche|Pfizer Breast Neoplasm May 2002 Phase 2
NCT00003622 James Ahlgren|George Washington University Prostate Cancer January 1999 Phase 2
NCT01104259 University of Washington|National Cancer Institute (NCI) Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Hereditary Breast/Ovarian Cancer - BRCA1|Hereditary Breast/Ovarian Cancer - BRCA2|Male Breast Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer July 16, 2010 Phase 1
NCT01242449 Vejle Hospital Breast Cancer November 2010 Phase 2
NCT00070304 Children's Oncology Group|National Cancer Institute (NCI) Lymphoma July 2004 Phase 2
NCT00431704 National Cancer Institute, Naples Metastatic Breast Cancer October 2007 Phase 2
NCT00325234 Eli Lilly and Company Breast Cancer June 2006 Phase 2
NCT01222715 National Cancer Institute (NCI) Adult Rhabdomyosarcoma|Childhood Alveolar Rhabdomyosarcoma|Childhood Pleomorphic Rhabdomyosarcoma|Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Childhood Rhabdomyosarcoma October 2010 Phase 2
NCT00389922 University of California, Davis|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific December 2005 Phase 1
NCT00041067 Southwest Oncology Group|National Cancer Institute (NCI) Breast Cancer September 2002 Phase 2
NCT00003259 Swiss Group for Clinical Cancer Research Prostate Cancer October 1997 Phase 2
NCT00002949 University of Chicago|National Cancer Institute (NCI) Bladder Cancer|Cervical Cancer|Endometrial Cancer|Vaginal Cancer July 1996 Phase 1
NCT00006088 H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific June 2000 Phase 1
NCT00088985 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation Breast Cancer January 2004 Phase 2
NCT00002583 NCIC Clinical Trials Group|National Cancer Institute (NCI)|Southwest Oncology Group|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Canadian Cancer Trials Group Lung Cancer July 1994 Phase 3
NCT00159094 Hematology Oncology Consultants|Ortho Biotech, Inc. Metastatic Breast Cancer October 2003 Phase 2
NCT01683682 Aktion Bronchialkarzinom e.V.|Boehringer Ingelheim Carcinoma, Non-Small-Cell Lung April 2013 Phase 1
NCT00441740 Hellenic Oncology Research Group|University Hospital of Crete Non Small Cell Lung Cancer April 2004 Phase 3
NCT00001944 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Breast Cancer|Cancer|Lung Cancer|Ovarian Cancer December 1999 Phase 1
NCT00005865 GlaxoSmithKline|National Cancer Institute (NCI) Lung Cancer April 2000 Phase 2
NCT02544243 Shandong Cancer Hospital and Institute Metastatic Breast Cancer September 2015 Phase 2
NCT00041470 University of Washington|Amgen|Bristol-Myers Squibb|GlaxoSmithKline Breast Cancer March 2001 Phase 1|Phase 2
NCT00309998 University of Rochester Lung Cancer September 2005 Phase 2
NCT00148291 West Japan Thoracic Oncology Group Lung Cancer June 1999 Phase 3
NCT00349089 Thoraxklinik am Universitätsklinikum Heidelberg Non-small Cell Lung Cancer October 2006 Phase 2
NCT00540982 City of Hope Medical Center|National Cancer Institute (NCI) Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific December 1996
NCT00287963 Medical University of South Carolina Lung Cancer February 2004 Phase 1
NCT00103233 Southwest Oncology Group|National Cancer Institute (NCI) Breast Cancer December 2004 Phase 3
NCT00015938 Southwest Oncology Group|National Cancer Institute (NCI) Breast Cancer May 2001 Phase 2
NCT01441596 Boehringer Ingelheim Breast Neoplasms|Neoplasm Metastasis October 2011 Phase 2
NCT00049660 European Organisation for Research and Treatment of Cancer - EORTC Breast Cancer September 2002 Phase 2|Phase 3
NCT00271271 Sanofi Non Small Cell Lung Cancer June 2003 Phase 2
NCT02223611 Hebei Medical University Fourth Hospital Non-small Cell Lung Cancer Stage Ⅱ|Non-small Cell Lung Cancer Stage ⅢA December 2014 Phase 2
NCT00003447 Istituto Nazionale per lo Studio e la Cura dei Tumori|National Cancer Institute (NCI) Lung Cancer July 1998 Phase 3
NCT00381940 National Cancer Institute (NCI) Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Childhood Lymphocyte Depletion Hodgkin Lymphoma|Childhood Lymphocyte Predominant Hodgkin Lymphoma|Childhood Mixed Cellularity Hodgkin Lymphoma|Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Childhood Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymp January 2007 Phase 2
NCT00403988 American University of Beirut Medical Center|Sanofi Breast Neoplasms June 2004 Phase 2
NCT01410214 Chinese Lung Cancer Surgical Group|Tianjin Medical University Cancer Institute and Hospital|Fudan University|Zhejiang Cancer Hospital|Beijing Cancer Hospital|Sun Yat-sen University|Chinese PLA General Hospital|Qingdao University|The First Affiliated Hospital of Soochow University|Harbin Medical University|Hebei Medical University Fourth Hospital|The Second People's Hospital of Sichuan Non-small Cell Lung Cancer Stage IIIA May 2011 Phase 2
NCT00006682 Washington Hospital Center|National Cancer Institute (NCI) Breast Cancer February 2000 Phase 2
NCT00169104 Dartmouth-Hitchcock Medical Center|Amgen Metastatic Breast Cancer July 2002 Phase 2|Phase 3
NCT00401427 National Cancer Institute, Naples Metastatic Breast Cancer November 2002 Phase 2
NCT00597116 Genzyme, a Sanofi Company|Sanofi Mesothelioma December 2007 Phase 2
NCT00003730 European Organisation for Research and Treatment of Cancer - EORTC Breast Cancer December 1998
NCT00003902 Swiss Group for Clinical Cancer Research Breast Cancer March 1999 Phase 1|Phase 2
NCT01125566 Boehringer Ingelheim Breast Neoplasms June 2010 Phase 3
NCT00277069 University of New Mexico Breast|Cancer May 2000 Phase 1|Phase 2
NCT00163748 Bayside Health Non-Hodgkin's Lymphoma|Hodgkin's Disease February 2001 Phase 2
NCT00683514 Pierre Fabre Medicament|Pierre Fabre Pharma GmbH NSCLC April 2005 Phase 3
NCT02919462 Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|Pierre Fabre Laboratories Carcinoma, Non-Small-Cell Lung|Secondary|Advanced Stage IIIB|High Thymidylate Synthase Expression March 2016 Phase 2
NCT02465736 Sun Yat-sen University Esophageal Squamous Cell Carcinoma|Esophageal Cancer|Oesophageal Cancer July 2015 Phase 3
NCT00026156 Southwest Oncology Group|National Cancer Institute (NCI) Lung Cancer November 2001 Phase 2
NCT00881387 University of Miami Lymphoma February 2009 Phase 2
NCT00724386 University of Chicago|Amgen Breast Cancer June 1999 Phase 1
NCT00503750 Emory University Breast Cancer April 2008 Phase 2
NCT02610140 Bayer|ImmunoGen and MorphoSys Mesothelioma December 3, 2015 Phase 2
NCT00868634 iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Arbeitskreis Klinische Studien|Roche Pharma AG Metastatic Breast Cancer February 2009 Phase 3
NCT00006760 Children's Oncology Group|National Cancer Institute (NCI) Lymphoma May 2001 Phase 2
NCT00014430 Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI) Breast Cancer November 1999 Phase 1
NCT00430001 Danish Breast Cancer Cooperative Group|Hoffmann-La Roche|Sanofi Breast Cancer May 2005 Phase 3
NCT00017459 Sanofi|National Cancer Institute (NCI) Lung Cancer July 2000 Phase 3
NCT00004096 Northwestern University|National Cancer Institute (NCI) Lung Cancer August 1999 Phase 1|Phase 2
NCT02281708 Seoul National University Hospital Stage Ib Lung Carcinoma October 2014 Phase 3
NCT00054197 CTI BioPharma|National Cancer Institute (NCI) Lung Cancer January 2003 Phase 3
NCT00480597 Ludwig-Maximilians - University of Munich Metastatic Breast Cancer October 2002 Phase 2
NCT00272558 Rigshospitalet, Denmark Malignant Pleural Mesothelioma September 2004 Phase 2
NCT00620971 Hellenic Oncology Research Group|University Hospital of Crete Non Small Cell Lung Cancer January 2008 Phase 2
NCT01220375 University Hospital Inselspital, Berne Myeloma April 2010 Phase 2
NCT00773188 Hoffmann-La Roche Non-Squamous Non-Small Cell Lung Cancer December 2008 Phase 1
NCT01126138 Chinese Academy of Medical Sciences|Hoffmann-La Roche Carcinoma, Invasive Ductal, Breast July 2010 Phase 3
NCT00193362 SCRI Development Innovations, LLC|Eli Lilly and Company|GlaxoSmithKline Lung Cancer June 2004 Phase 3
NCT00079287 Japan Multinational Trial Organization|National Cancer Institute (NCI) Lung Cancer March 2001 Phase 3
NCT01050322 Latin American Cooperative Oncology Group|GlaxoSmithKline BRMS1|Performance Status Zero to Two for Beginning the Study|Patient With a Maximum of One Chemotherapy|Patient With Progression After Taxanes November 2009 Phase 2
NCT01325428 Boehringer Ingelheim Breast Neoplasms August 2011 Phase 2
NCT00057798 Roswell Park Cancer Institute Lung Cancer March 2000 Phase 2
NCT01020864 Per Pfeiffer|Odense University Hospital Head and Neck Neoplasms January 2010 Phase 2
NCT02897986 Assistance Publique Hopitaux De Marseille Pediatric Cancer January 2017 Phase 1
NCT00006215 Amgen|National Cancer Institute (NCI) Lung Cancer October 1999 Phase 2
NCT00163761 Bayside Health Non-Hodgkin's Lymphoma|Hodgkin's Disease December 2002 Phase 2
NCT01196078 Hoffmann-La Roche Non-Small Cell Lung Cancer February 2007 Phase 4
NCT00194740 University of Washington|Aventis Pharmaceuticals Breast Neoplasm November 1997 Phase 2
NCT03191786 Hoffmann-La Roche Non-Small Cell Lung Cancer September 1, 2017 Phase 3
NCT00265694 Inje University Non-Small Cell Lung Cancer Phase 3
NCT01443078 Memorial Sloan Kettering Cancer Center|Eli Lilly and Company|United States Department of Defense Lung Cancer October 2011 Phase 2
NCT00042315 QLT Inc. Stage IIIb Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer June 2002 Phase 3
NCT00006029 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Lymphoma July 2000 Phase 1|Phase 2
NCT02362958 Sun Yat-sen University HER2 Positive Breast Cancer February 2015 Phase 2
NCT02954055 International Breast Cancer Study Group Breast Cancer May 2017 Phase 2
NCT00002813 Gynecologic Oncology Group|National Cancer Institute (NCI) Cervical Cancer August 1997 Phase 2
NCT00298415 Intergroupe Francophone de Cancerologie Thoracique NSCLC March 2006 Phase 3
NCT00253591 Medical Research Council|National Cancer Institute (NCI) Lung Cancer June 2005 Phase 2|Phase 3
NCT01029678 University Hospital, Limoges|Pierre Fabre Laboratories Non Small Cell Lung Cancer January 2010 Phase 2
NCT02733380 Henan Cancer Hospital Diffuse Large B-cell Lymphoma May 2016 Phase 2
NCT00003587 Southwest Oncology Group|National Cancer Institute (NCI) Lung Cancer October 1998 Phase 2
NCT02607215 Fudan University Metastatic Breast Cancer November 2015 Phase 2
NCT00003584 University of New Mexico Kidney Cancer July 1998 Phase 2
NCT00462787 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Leukemia April 2007 Phase 1
NCT00636311 Istituto Clinico Humanitas Hodgkin Disease February 2008 Phase 2
NCT00064077 Gynecologic Oncology Group|National Cancer Institute (NCI) Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma|Stage IVB Cervical Cancer May 2003 Phase 3
NCT00337194 National Cancer Institute (NCI) Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma April 2006 Phase 2
NCT00004105 New York University School of Medicine|National Cancer Institute (NCI) Leukemia|Lymphoma|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific September 1998 Phase 1|Phase 2
NCT00627354 Groupe D'Etude des Tumeurs Uro-Genitales|National Cancer Institute (NCI) Prostate Cancer September 2006 Phase 2
NCT01271725 Boehringer Ingelheim Breast Neoplasms May 24, 2011 Phase 2
NCT02985658 University of Washington|AbbVie Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation|Triple-Negative Breast Cancer
NCT02497118 Tianjin Medical University Cancer Institute and Hospital Non Small Cell Lung Cancer August 2010 Phase 4
NCT00006372 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific February 2000 Phase 1
NCT00401492 National Cancer Institute, Naples Non Small Cell Lung Cancer June 2002 Phase 2
NCT02229149 US Oncology Research|Genentech, Inc. Breast Neoplasms|Malignant Tumor of the Breast December 2014 Phase 2
NCT00842712 Merck KGaA Carcinoma, Non-Small-Cell Lung February 2009 Phase 2
NCT00004100 Istituto Nazionale per lo Studio e la Cura dei Tumori|NCIC Clinical Trials Group|National Cancer Institute (NCI) Lung Cancer November 1998 Phase 3
NCT01884428 Armando Santoro, MD|Istituto Clinico Humanitas Hodgkin's Lymphoma July 2011 Phase 1
NCT00345059 National Cancer Institute, Naples Advanced Non-Small Cell Lung Cancer May 2005 Phase 3
NCT01784549 IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Azienda Sanitaria Locale di Cagliari|Azienda Ospedaliera San Gerardo di Monza|Ospedale Santa Croce-Carle Cuneo|Azienda Ospedaliera S. Maria della Misericordia|Istituto Tumori Giovanni Paolo II, BARI|Azienda Ospedaliera dei Colli|Azienda Ospedaliera Santa Maria Degli Angeli|Azienda Ospedaliera San Camillo Forlanini|Azienda Ospedaliera San Giovanni Battista|Azienda Ospedaliera Universitaria Integrata Verona|Azienda Sanitaria Locale n.2 Savonese|ASL TO4, Chivasso|Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento|Istituto Clinico Humanitas|Azienda Ospedaliera Sant'Andrea, Roma|Azienda Ospedaliera, Ospedale Civile di Legnano|Azienda Ospedaliera Spedali Riuniti di Livorno, Livorno Non Small Cell Lung Cancer July 2012 Phase 2
NCT00193921 Trans-Tasman Radiation Oncology Group (TROG)|Cancer Council Queensland|Victorian Cancer Council Non Small Cell Lung Carcinoma February 2003 Phase 2
NCT02991482 European Thoracic Oncology Platform|Merck Sharp & Dohme Corp.|Frontier Science Foundation, Hellas Pleural Mesothelioma Malignant Advanced May 2017 Phase 3
NCT00006114 Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI) Prostate Cancer May 1999 Phase 2
NCT00168883 Charite University, Berlin, Germany|Bristol-Myers Squibb|Pierre Fabre Pharma GmbH Carcinoma, Non-Small-Cell Lung October 2002 Phase 2
NCT02795884 Yonsei University NSCLC June 2016 Phase 3
NCT00434668 University Hospital, Antwerp|Universiteit Antwerpen|Sanofi Non-small Cell Lung Cancer December 2005 Phase 2
NCT00842595 French Innovative Leukemia Organisation Diffuse Large B-Cell Lymphoma December 2003 Phase 2
NCT00004093 Northwestern University|National Cancer Institute (NCI) Lung Cancer August 1999 Phase 1|Phase 2
NCT00198432 Intergroupe Francophone de Cancerologie Thoracique|Bristol-Myers Squibb|Pierre Fabre Laboratories|Ligue contre le cancer, France NSCLC Stage IIIB|Concomitant Radiochemotherapy March 2002 Phase 2
NCT00225173 Stanford University|National Cancer Institute (NCI) Hodgkin Disease October 2001 Phase 2
NCT01835236 Swiss Group for Clinical Cancer Research Metastatic Breast Cancer April 29, 2013 Phase 2
NCT02555657 Merck Sharp & Dohme Corp. Metastatic Triple Negative Breast Cancer October 13, 2015 Phase 3
NCT00194779 University of Washington|National Cancer Institute (NCI) Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer October 2003 Phase 2
NCT01454934 Eisai Inc. Non-Small Cell Lung Cancer (NSCLC) September 2011 Phase 3
NCT00392691 Swiss Group for Clinical Cancer Research Lymphoma October 2006 Phase 1
NCT00280878 Bayside Health Non-Hodgkin's Lymphoma (CD20+) January 2006 Phase 2
NCT02977169 Shanghai Chest Hospital Non-small Cell Lung Cancer Stage IIIA|Radiotherapy November 2016 Phase 2
NCT01687439 Fudan University Non-small Cell Lung Cancer December 2008 Phase 2
NCT00215930 H. Lee Moffitt Cancer Center and Research Institute|Eli Lilly and Company|Aventis Pharmaceuticals Carcinoma, Non-Small-Cell Lung February 2004 Phase 2
NCT00863512 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Lung Cancer March 2009 Phase 3
NCT02574455 Immunomedics, Inc. Breast Cancer March 31, 2017 Phase 3
NCT00401609 National Cancer Institute, Naples Small Cell Lung Cancer November 2000 Phase 1|Phase 2
NCT02352948 AstraZeneca Non - Small Cell Lung Cancer NSCLC January 13, 2015 Phase 3
NCT01097317 Wales Cancer Trials Unit|National Cancer Institute (NCI) Chemotherapeutic Agent Toxicity|Fatigue|Lung Cancer|Musculoskeletal Complications September 2009 Phase 2
NCT02492711 MacroGenics HER-2 Positive Breast Cancer|Metastatic Neoplasm July 2015 Phase 3
NCT03161054 Fondazione Italiana Linfomi ONLUS Aggressive Non-Hodgkin Lymphoma June 2017 Phase 2
NCT02331251 Western Regional Medical Center Advanced Cancer|Breast Cancer|Sarcoma|Pancreatic Cancer|Small Cell Lung Cancer|Ovarian December 2014 Phase 1|Phase 2
NCT00795678 Case Comprehensive Cancer Center|United States Department of Defense|National Cancer Institute (NCI) Breast Cancer|Metastatic Cancer September 2008
NCT00005847 Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Prostate Cancer January 2001 Phase 2
NCT00455572 GlaxoSmithKline Lung Cancer, Non-Small Cell May 11, 2007 Phase 1
NCT00004237 Royal Marsden NHS Foundation Trust|National Cancer Institute (NCI) Breast Cancer October 1998 Phase 2
NCT02777788 Shanghai University of Traditional Chinese Medicine|Shanghai Chest Hospital|Shanghai Pulmonary Hospital, Shanghai, China Cancer September 2014 Phase 2|Phase 3
NCT02117024 Heat Biologics Non Small Cell Lung Cancer July 2014 Phase 2
NCT00354393 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Malignant Mesothelioma August 2002 Phase 2
NCT02974426 Shanghai Chest Hospital|Shanghai Pulmonary Hospital, Shanghai, China|Fudan University|Shanghai Zhongshan Hospital|Ruijin Hospital|RenJi Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Non-small Cell Lung Cancer Stage IIIA|Radiotherapy November 2016 Phase 3
NCT00388349 Stanford University|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID) Hodgkin Disease|Hodgkin's Lymphoma|Lymphoma September 2001 Phase 2
NCT00499109 H. Lee Moffitt Cancer Center and Research Institute|Sanofi Non-Small Cell Lung Cancer May 2007 Phase 3
NCT01038037 Vejle Hospital Non Small Cell Lung Cancer January 2010 Phase 2
NCT01137994 GlaxoSmithKline Neoplasms, Breast October 2011 Phase 2
NCT00194792 University of Washington|National Cancer Institute (NCI) Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer August 2005 Phase 2
NCT02514681 Japan Breast Cancer Research Group|Chugai Pharmaceutical HER2-positive Locally Advanced or Metastatic Breast Cancer October 2015 Phase 3
NCT01683175 Tianjin Medical University Cancer Institute and Hospital|Roche Pharma AG Non-small Cell Lung Cancer Stage III August 2012 Phase 2
NCT02213744 Merrimack Pharmaceuticals Breast Cancer|HER2 Positive Breast Cancer July 2014 Phase 2|Phase 3
NCT02486718 Hoffmann-La Roche Non-Small Cell Lung Cancer October 31, 2015 Phase 3
NCT00088530 CTI BioPharma Lymphoma, Non-Hodgkin July 2004 Phase 3
NCT00476827 Duke University|Genentech, Inc. Breast Cancer May 2007 Phase 2
NCT00736814 Yonsei University|National Cancer Institute (NCI) Lung Cancer June 2008 Phase 2
NCT00005838 National Cancer Institute (NCI)|Radiation Therapy Oncology Group|National Center for Complementary and Integrative Health (NCCIH) Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer March 2000 Phase 3
NCT02940990 Shanghai Chest Hospital NSCLC|SBRT|GM-CSF November 2016 Phase 2
NCT00333294 AstraZeneca Non-Small Cell Lung Cancer September 2004 Phase 2
NCT00705549 Hellenic Oncology Research Group|University Hospital of Crete Non-Small-Cell Lung Cancer February 2008 Phase 2
NCT02579564 Xinqiao Hospital of Chongqing Malignant Hydrothorax|Non Small Cell Lung Cancer October 2016 Phase 3
NCT02644252 Vejle Hospital Lung Cancer January 2016 Phase 3
NCT00324805 National Cancer Institute (NCI)|Cancer and Leukemia Group B|NCIC Clinical Trials Group|North Central Cancer Treatment Group|Southwest Oncology Group Stage IB Non-Small Cell Lung Carcinoma AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7 June 1, 2007 Phase 3
NCT02915744 Nektar Therapeutics Metastasis|Breast Cancer November 2016 Phase 3
NCT00030459 British Thoracic Society|Medical Research Council|National Cancer Institute (NCI) Malignant Mesothelioma November 2000 Phase 2
NCT00005825 Raghu Nandan, M.D., Inc|National Cancer Institute (NCI) Lung Cancer September 1998 Phase 2
NCT00235235 Hoosier Cancer Research Network|United States Department of Defense|Indiana University School of Medicine|Walther Cancer Institute Breast Cancer September 2005
NCT01026220 Children's Oncology Group|National Cancer Institute (NCI) Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma December 2009 Phase 3
NCT00686959 Eli Lilly and Company Non Small Cell Lung Cancer September 2008 Phase 3
NCT01209520 University of Miami Lung Cancer|Non Small Cell Lung Carcinoma|Hypermethylation July 2009
NCT02344472 Prof. W. Janni|Roche Pharma AG|DETECT study group|University of Ulm Metastatic Breast Cancer September 2015 Phase 3
NCT00003400 University of Maryland Prostate Cancer September 1998 Phase 2
NCT00477035 Sally Arai|Stanford University Leukemia|Multiple Myeloma May 2006 Phase 1
NCT00002823 Gustave Roussy, Cancer Campus, Grand Paris Lung Cancer February 1995 Phase 3
NCT00075699 Medical Research Council|National Cancer Institute (NCI) Malignant Mesothelioma September 2003 Phase 3
NCT00302003 Children's Oncology Group|National Cancer Institute (NCI) Childhood Favorable Prognosis Hodgkin Lymphoma|Childhood Lymphocyte Depletion Hodgkin Lymphoma|Childhood Mixed Cellularity Hodgkin Lymphoma|Childhood Nodular Sclerosis Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma February 2006 Phase 3
NCT00083083 American College of Radiology Imaging Network|National Cancer Institute (NCI)|Radiation Therapy Oncology Group Lung Cancer March 2005 Phase 2
NCT00002887 Ottawa Regional Cancer Centre|National Cancer Institute (NCI) Lung Cancer July 1995 Phase 1
NCT00055887 Spectrum Pharmaceuticals, Inc Lung Cancer November 2002 Phase 3
NCT02998528 Bristol-Myers Squibb Non Small Cell Lung Cancer January 13, 2017 Phase 3
NCT01698281 AEterna Zentaris Breast Cancer December 2012 Phase 2
NCT00003240 National Cancer Institute (NCI) Lung Cancer October 1995 Phase 3
NCT00379457 European Paediatric Soft Tissue Sarcoma Study Group|Italian Association for Pediatric Hematology Oncology|Children's Cancer and Leukaemia Group|Dutch Childhood Oncology Group|National Cancer Institute (NCI) Sarcoma June 2006 Phase 3
NCT00003159 Medical Research Council|European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) Lung Cancer August 1997 Phase 3
NCT00920153 French Innovative Leukemia Organisation Lymphoma May 2008 Phase 3
NCT00574496 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Lymphoma November 2007 Phase 2
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 1.2838 mL 6.4191 mL 12.8381 mL
5 mM 0.2568 mL 1.2838 mL 2.5676 mL
10 mM 0.1284 mL 0.6419 mL 1.2838 mL
Animal Administration
[4]

Vinorelbine is diluted in 0.9% NaCl to a concentration of 1.5 mg/mL.

As defined by the study, VRL1 is diluted in 0.9% NaCl to a concentration of 1.5 mg/mL, and given IV over 5 minutes. The intended treatment interval is 7 days for up to 4 treatments. After receiving 4 weekly doses, cats are eligible to continue VRL treatment every 2 weeks at the owner's expense. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

778.93

Formula

C₄₅H₅₄N₄O₈

CAS No.

71486-22-1

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Vinorelbine
Cat. No.:
HY-12053
Quantity: